MRMD on OTC
MARIMED INC.
American medicinal chemicals and botanical products company1
In its 2026 annual report the company says: “We are a multi-state cannabis operator in the United States, headquartered in Norwood, Massachusetts, dedicated to improving lives every day through our high-quality products, our actions, and our values. We develop, own, and manage seed to sale state-licensed, state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of medicinal and adult-use cannabis.”4 Its shares trade on OTC under the symbol MRMD.1
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Cronos Group Inc, Natural Alternatives International or Glass House Brands Inc., or pick any stock.
- TickerMRMD on OTC1
- IndustryMedicinal Chemicals & Botanical Products1
- HeadquartersNorwood, Massachusetts1
- Incorporated inDE2
- Business address10 Oceana Way, 2Nd Floor, Norwood, Ma 020622
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
Unless expressly indicated or the context requires otherwise, the terms "MariMed", "company", "we", "us", "our", and "Company" in this document refer to MariMed Inc., a Delaware corporation, and, where appropriate, its subsidiaries.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product Sales brought in 56% of the revenue MARIMED INC. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product Sales | $91.3M | $89.0M |
| Product Sales - Wholesale | $62.9M | $69.6M |
| Other | $3.5M | $1.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue64¢$101.9M
- Other costs34¢$54.3M
- Income tax2¢$3.6M
Out of $159.8M in revenue.5 The company lost money this year.
Where each dollar of operating cash went, fiscal 2025
- Capital spending15¢$1.2M
- Kept or used elsewhere85¢$6.5M
Out of $7.7M of cash from operations.5
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $159.8M | $157.7M |
| Cost of revenue | $101.9M | $95.1M |
| Gross profit | $57.9M | $62.6M |
| Personnel | $28.5M | $27.1M |
| Marketing and promotion | $4.0M | $6.7M |
| General and administrative | $26.1M | $25.6M |
| Acquisition-related and other | $486.0K | $951.0K |
| Bad debt expense (income) | $1.6M | -$336.0K |
| Total operating expenses | $60.7M | $60.0M |
| (Loss) income from operations | -$2.8M | $2.6M |
| Interest expense | -$7.5M | -$6.9M |
| Interest income | $177.0K | $114.0K |
| Other expense, net | -$717.0K | -$50.0K |
| Total interest and other expense, net | -$8.0M | -$6.9M |
| Loss before income taxes | -$10.9M | -$4.3M |
| Provision for income taxes | $3.6M | $8.2M |
| Net loss | -$14.5M | -$12.4M |
| Less: Net income attributable to noncontrolling interests | $28.0K | $37.0K |
| Net loss attributable to common stockholders | -$14.5M | -$12.5M |
| Basic (in dollars per share) | -$0.04 | -$0.03 |
| Diluted (in dollars per share) | -$0.04 | -$0.03 |
| Basic (in shares) | 390.1M shares | 379.2M shares |
| Diluted (in shares) | 390.1M shares | 379.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $8.9M | $7.3M | |
| Accounts receivable, net | $9.1M | $8.7M | |
| Inventory | $36.6M | $33.5M | |
| Deferred rents receivable | $0 | $556.0K | |
| Notes receivable, current portion | $866.0K | $52.0K | |
| Other current assets | $3.8M | $3.4M | |
| Total current assets | $59.3M | $53.5M | |
| Property and equipment, net | $89.4M | $94.2M | |
| Intangible assets, net | $17.2M | $18.6M | |
| Goodwill | $24.0M | $15.8M | $12.0M |
| Notes receivable, net of current portion | $0 | $840.0K | |
| Operating lease right-of-use assets | $7.7M | $8.7M | |
| Finance lease right-of-use assets | $4.0M | $4.1M | |
| Other assets | $931.0K | $11.2M | |
| Total assets | $202.6M | $207.0M | |
| Mortgages and notes payable, current portion | $2.6M | $5.1M | |
| Accounts payable | $14.6M | $13.2M | |
| Accrued expenses and other | $9.5M | $4.4M | |
| Deferred revenue | $1.4M | $1.3M | |
| Income taxes payable | $27.0M | $21.9M | |
| Operating lease liabilities, current portion | $2.0M | $2.0M | |
| Finance lease liabilities, current portion | $2.1M | $2.0M | |
| Total current liabilities | $59.1M | $50.0M | |
| Mortgages and notes payable, net of current portion | $70.2M | $69.9M | |
| Operating lease liabilities, net of current portion | $6.6M | $7.5M | |
| Finance lease liabilities, net of current portion | $2.0M | $1.9M | |
| Other liabilities | $0 | $100.0K | |
| Total liabilities | $137.8M | $129.4M | |
| Total mezzanine equity | $14.7M | $19.0M | |
| Undesignated preferred stock, $0.001 par value; 32,659,235 shares authorized; zero shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 700,000,000 shares authorized; 396,911,368 and 381,476,581 shares issued and outstanding at December 31, 2025 and 2024, respectively | $397.0K | $381.0K | |
| Additional paid-in capital | $179.4M | $173.4M | |
| Accumulated deficit | -$127.9M | -$113.4M | |
| Noncontrolling interests | -$1.9M | -$1.8M | |
| Total stockholders equity | $50.0M | $58.5M | $68.9M |
| Total liabilities, mezzanine equity, and stockholders equity | $202.6M | $207.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized (in shares) | 32.7M shares | 32.7M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 700.0M shares | 700.0M shares | |
| Common stock, issued (in shares) | 396.9M shares | 381.5M shares | |
| Common stock, outstanding (in shares) | 396.9M shares | 381.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash, cash equivalents and restricted cash | $8.9M | $7.3M | |
| Accounts receivable, net | $9.1M | $8.7M | |
| Inventory | $36.6M | $33.5M | |
| Deferred rents receivable | $0 | $556.0K | |
| Notes receivable, current portion | $866.0K | $52.0K | |
| Other current assets | $3.8M | $3.4M | |
| Total current assets | $59.3M | $53.5M | |
| Property and equipment, net | $89.4M | $94.2M | |
| Intangible assets, net | $17.2M | $18.6M | |
| Goodwill | $24.0M | $15.8M | $12.0M |
| Notes receivable, net of current portion | $0 | $840.0K | |
| Operating lease right-of-use assets | $7.7M | $8.7M | |
| Finance lease right-of-use assets | $4.0M | $4.1M | |
| Other assets | $931.0K | $11.2M | |
| Total assets | $202.6M | $207.0M | |
| Mortgages and notes payable, current portion | $2.6M | $5.1M | |
| Accounts payable | $14.6M | $13.2M | |
| Accrued expenses and other | $9.5M | $4.4M | |
| Deferred revenue | $1.4M | $1.3M | |
| Income taxes payable | $27.0M | $21.9M | |
| Operating lease liabilities, current portion | $2.0M | $2.0M | |
| Finance lease liabilities, current portion | $2.1M | $2.0M | |
| Total current liabilities | $59.1M | $50.0M | |
| Mortgages and notes payable, net of current portion | $70.2M | $69.9M | |
| Operating lease liabilities, net of current portion | $6.6M | $7.5M | |
| Finance lease liabilities, net of current portion | $2.0M | $1.9M | |
| Other liabilities | $0 | $100.0K | |
| Total liabilities | $137.8M | $129.4M | |
| Total mezzanine equity | $14.7M | $19.0M | |
| Undesignated preferred stock, $0.001 par value; 32,659,235 shares authorized; zero shares issued and outstanding at December 31, 2025 and 2024 | $0 | $0 | |
| Common stock, $0.001 par value; 700,000,000 shares authorized; 396,911,368 and 381,476,581 shares issued and outstanding at December 31, 2025 and 2024, respectively | $397.0K | $381.0K | |
| Additional paid-in capital | $179.4M | $173.4M | |
| Accumulated deficit | -$127.9M | -$113.4M | |
| Noncontrolling interests | -$1.9M | -$1.8M | |
| Total stockholders equity | $50.0M | $58.5M | $68.9M |
| Total liabilities, mezzanine equity, and stockholders equity | $202.6M | $207.0M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, authorized (in shares) | 32.7M shares | 32.7M shares | |
| Preferred stock, issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, authorized (in shares) | 700.0M shares | 700.0M shares | |
| Common stock, issued (in shares) | 396.9M shares | 381.5M shares | |
| Common stock, outstanding (in shares) | 396.9M shares | 381.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss attributable to common stockholders | -$14.5M | -$12.5M |
| Net income attributable to noncontrolling interests | $28.0K | $37.0K |
| Depreciation and amortization of property and equipment | $8.1M | $7.9M |
| Amortization of intangible assets | $3.4M | $2.9M |
| Stock-based compensation | $1.9M | $1.1M |
| Amortization of warrants issued as payment for services received | $0 | $218.0K |
| Amortization of debt discount | $459.0K | $358.0K |
| Amortization of debt issuance costs | $73.0K | $73.0K |
| Payment-in-kind interest | $30.0K | $104.0K |
| Bad debt expense (income) | $1.6M | -$336.0K |
| Obligations settled with common stock | $3.0K | $10.0K |
| Loss on disposal of assets | $834.0K | $13.0K |
| Loss on changes in fair value of investments | $0 | $145.0K |
| Accounts receivable, net | -$429.0K | -$1.2M |
| Inventory | -$6.0K | -$8.2M |
| Deferred rents receivable | $12.0K | $74.0K |
| Other current assets | $1.0M | $883.0K |
| Other assets | -$2.6M | $1.4M |
| Accounts payable | $841.0K | $4.2M |
| Accrued expenses and other | $3.2M | $1.8M |
| Deferred revenue | $65.0K | $303.0K |
| Income taxes payable | $3.7M | $7.5M |
| Net cash provided by operating activities | $7.7M | $6.8M |
| Purchases of property and equipment | -$1.2M | -$12.0M |
| Business acquisitions, net of cash acquired | $231.0K | -$4.2M |
| Advances toward future business acquisitions | -$50.0K | -$100.0K |
| Purchases and renewals of cannabis licenses | -$465.0K | -$712.0K |
| Proceeds from notes receivable | $26.0K | $50.0K |
| Return on investment | $0 | $44.0K |
| Proceeds from disposal of assets | $45.0K | $22.0K |
| Due from third party | $0 | -$227.0K |
| Net cash used in investing activities | -$1.4M | -$17.1M |
| Proceeds from Construction to Permanent Commercial Real Estate Mortgage Loan | $0 | $5.1M |
| Proceeds from mortgages | $2.0M | $1.2M |
| Payment of third-party debt issuance costs in connection with debt | -$9.0K | $0 |
| Principal payments of mortgages | -$1.5M | -$382.0K |
| Repayment and retirement of mortgages | -$689.0K | $0 |
| Principal payments of promissory notes | -$3.1M | -$1.2M |
| Principal payments of finance leases | -$1.3M | -$1.6M |
| Distributions | -$137.0K | -$139.0K |
| Net cash (used in) provided by financing activities | -$4.7M | $3.0M |
| Net increase (decrease) to cash, cash equivalents and restricted cash | $1.6M | -$7.4M |
| Cash paid for interest | $6.9M | $6.7M |
| Cash (refunded) paid for income taxes, net | -$713.0K | $705.0K |
| Common stock issued to purchase property and equipment | $0 | $396.0K |
| Present value of promissory notes issued as purchase consideration | $0 | $3.0M |
| Entry into new finance leases | $1.3M | $2.9M |
| Write-off of finance leases | $0 | $1.1M |
| Common stock issued as purchase consideration | $0 | $991.0K |
| Notes payable issued to purchase property and equipment | $447.0K | $0 |
| Common stock issued under licensing agreement | $0 | $10.0K |
| Conversion of preferred stock to common stock | $4.3M | $0 |
| Return of common stock to the Company in connection with withholding taxes | $83.0K | $41.0K |
| Adjustment to purchase price allocation to reclassify certain acquired intangible assets to goodwill | $0 | $3.8M |
No quarter-by-quarter statement was filed.
Corporate structure
MARIMED INC. sits at the top of its group. 18 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
- MARIMED INC. Norwood, Massachusetts
- Allgreens Dispensary LLC Subsidiary · Illinois, United States
- ARL Healthcare Inc. Subsidiary · Massachusetts, United States
- First State Compassion Center Subsidiary · Delaware, United States
- Green Growth Group Inc. Subsidiary · Illinois, United States
- Hartwell Realty Holdings LLC Subsidiary · Massachusetts, United States
- Kind Therapeutics USA LLC Subsidiary · Maryland, United States
- KPG of Anna LLC Subsidiary · Illinois, United States
- KPG of Harrisburg LLC Subsidiary · Illinois, United States
- Mari Holdings IL LLC Subsidiary · Massachusetts, United States
- Mari Holdings MD LLC Subsidiary · Massachusetts, United States
- Mari Holdings Metropolis LLC Subsidiary · Massachusetts, United States
- Mari Holdings Mt. Vernon LLC Subsidiary · Massachusetts, United States
- MariMed Advisors Inc. Subsidiary · Massachusetts, United States
- MariMed OH LLC Subsidiary · Ohio, United States
- Mia Development LLC Subsidiary · Massachusetts, United States
- MMA Hemp LLC Subsidiary · Massachusetts, United States
- MMMO LLC Subsidiary · Missouri, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What MARIMED INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $116.5M5 Dec 31, 2025 | $115.8M5 Dec 31, 2024 | +0.6% |
| Accumulated depreciation | $27.1M5 Dec 31, 2025 | $21.6M5 Dec 31, 2024 | +25.3% |
| Property and equipment, net | $89.4M5 Dec 31, 2025 | $94.2M5 Dec 31, 2024 | −5.1% |
| Finance-lease assets | $4.0M5 Dec 31, 2025 | $4.1M5 Dec 31, 2024 | −1.2% |
| Operating-lease assets (leased space) | $7.7M5 Dec 31, 2025 | $8.7M5 Dec 31, 2024 | −11.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $7.3M10 Dec 31, 2024 | $14.6M10 Dec 31, 2023 | −50.3% |
| Marketable securities, current | $010 Dec 31, 2024 | $88.0K10 Dec 31, 2023 | −100.0% |
| Long-term investments | $010 Dec 31, 2024 | $221.0K10 Dec 31, 2023 | −100.0% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $24.0M5 Dec 31, 2025 | $15.8M5 Dec 31, 2024 | +51.8% |
| Accumulated amortization | $10.5M5 Dec 31, 2025 | $7.1M5 Dec 31, 2024 | +47.8% |
| Finite-lived intangibles, net | $17.2M5 Dec 31, 2025 | $18.6M5 Dec 31, 2024 | −7.7% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $36.6M5 Dec 31, 2025 | $33.5M5 Dec 31, 2024 | +9.3% |
| Work in process | $9.6M5 Dec 31, 2025 | $4.8M5 Dec 31, 2024 | +101.1% |
| Finished goods | $12.9M5 Dec 31, 2025 | $10.3M5 Dec 31, 2024 | +24.3% |
Properties, in its own words
As of December 31, 2025, the Company maintained the following principal facilities:
Massachusetts
The rest of Item 2
Beverly
The Company operates a dispensary in Beverly in a retail space under a lease that expires in July 2026, with options to extend the term for three additional five-year periods through 2041.
New Bedford
The Company owns an industrial property, of which the Company has developed approximately half into a cannabis cultivation and processing facility in which it conducts wholesale operations. The remaining portion of the property was rented to a non-cannabis manufacturing company through November 2023. The Company intends to expand its cannabis wholesale operations to include the entire property. The mortgage on this property and the Middleborough, Massachusetts property described below was previously held by Bank of New England; however, in November 2023, the Company repaid this mortgage and refinanced both properties in connection with a new Construction to Permanent Commercial Real Estate Mortgage Loan with Needham Bank (the "CREM Loan"). As a result, the mortgage on the New Bedford and Middleborough properties is now held by Needham Bank, and matures in 2033.
Norwood
The Company leases its corporate headquarters under a lease that expires in 2028 and which includes a five-year extension option.
Middleborough
The Company owns and operates a retail and warehouse building located in a high-traffic area. A portion of the building houses the Company's flagship Massachusetts retail dispensary, with the remaining square footage used as a warehouse. The mortgage on this property and the New Bedford, Massachusetts property described above was previously held by Bank of New England; however, in November 2023, the Company repaid this mortgage and refinanced both properties in connection with the CREM Loan. As a result, the mortgage on the New Bedford and Middleborough properties is now held by Needham Bank, and matures in 2033.
Quincy
The Company leases a building that houses both a dispensary and a cultivation facility under a lease that expires in 2038.
Delaware
Lewes
The Company leases retail space located in a multi-use building under a lease that expires in 2027 in which in operates a dispensary.
Milford
The Company leases a warehouse, 60% of which it developed into a cultivation facility, with plans to develop the remaining square footage into a processing facility. The lease term expires in March 2030, with an option to extend the term for three additional five-year periods.
Wilmington
The Company owns a cannabis cultivation, processing, and dispensary facility located in a business park. The property is secured under a mortgage with the Bank of New England that matures in 2031.
Illinois
Anna
The Company owns and operates a free-standing cannabis dispensary in a building that is secured under a mortgage with DuQuoin State Bank that matures in May 2045 (the "DSQ Mortgage").
Casey
The Company owns and operates a free-standing cannabis dispensary.
Harrisburg
The Company owns and operates a free-standing cannabis dispensary, also secured under the DSQ Mortgage.
Metropolis
The Company owns and operates a free-standing cannabis dispensary, secured under a mortgage with DuQuoin State Bank that matures in 2041.
Mt. Vernon
The Company owns and operates a grow and production facility. The premises are secured under a mortgage with DuQuoin State Bank that matures in 2042.
The Company also owns and operates a free-standing cannabis dispensary, secured under a mortgage with DuQuoin State Bank that matures in 2041.
Maryland
Annapolis
The Company owns a free standing industrial building in which it operates a cannabis dispensary.
Hagerstown
The Company owns a manufacturing facility that it has developed into and in which it operates a cannabis cultivation and production facility.
Upper Marlboro
The Company operates a cannabis dispensary in a space that it rents on a month-to-month basis.
Ohio
Tiffin
The Company operates a dispensary in Tiffin under a lease that expires in 2033.
Item 2 of the 10-K filed Mar 12, 2026.4
Leadership
Who has led MARIMED INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerRobert N. Fireman Nov 25, 2019 to Oct 31, 202214
- PresidentRobert N. Fireman Nov 25, 2019 to Oct 31, 202214
- Chief financial officerMario Pinho Aug 15, 2024 to now15
- Chief financial officerSusan M. Villare May 18, 2022 to Mar 14, 202316
Board members and other officers (8)
- Chief Commercial OfficerRyan Crandall Apr 14, 2025 to now17
- Board memberKathleen Tucker Apr 19, 2023 to now18
- Board memberDavid R. Allen Jun 28, 2019 to now19
- Board memberEva M.d. Selhub Oct 1, 2019 to now20
- Board memberThomas Kidrin Feb 1, 2018 to May 3, 201921
- Board memberEdward J. Gildea Feb 15, 2017 to now22
- Board memberJay Coleman Aug 19, 2011 to Aug 19, 201123
- Board memberRobert N. Fireman Aug 19, 2011 to Oct 31, 202224
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- ARL Healthcare Inc. Massachusetts3
- Allgreens Dispensary LLC Illinois3
- First State Compassion Center Delaware3
- Green Growth Group Inc. Illinois3
- Hartwell Realty Holdings LLC Massachusetts3
- KPG of Anna LLC Illinois3
- KPG of Harrisburg LLC Illinois3
- Kind Therapeutics USA LLC Maryland3
- MMA Hemp LLC Massachusetts3
- MMMO LLC Missouri3
- Mari Holdings IL LLC Massachusetts3
- Mari Holdings MD LLC Massachusetts3
- Mari Holdings Metropolis LLC Massachusetts3
- Mari Holdings Mt. Vernon LLC Massachusetts3
- MariMed Advisors Inc. Massachusetts3
- MariMed OH LLC Ohio3
- Mia Development LLC Massachusetts3
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- WORLDS ONLINE INC.Jun 9, 2011 to May 15, 20172
Timeline
- Sep 23, 20268-K Other events25
- Aug 12, 20268-K Results of operations26
- Jun 8, 20268-K Shareholder vote27
- May 13, 20268-K Results of operations28
- Mar 11, 20268-K Results of operations29
- Mar 2, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares30
- Nov 5, 20258-K Results of operations31
- Aug 6, 20258-K Results of operations32
- Jun 13, 20258-K Shareholder vote33
- May 7, 20258-K Results of operations34
- Mar 5, 20258-K Results of operations35
- Nov 6, 20248-K Results of operations36
- Nov 25, 2019New chief executive Robert N. Fireman becomes CEO14
Calendar
Coming up
- Around Nov 11, 2026Next results, estimated About a quarter after its last report. The company hasn't announced the date.
When it reported results
- Aug 12, 2026Reported quarterly or annual results26
- May 13, 2026Reported quarterly or annual results28
- Mar 11, 2026Reported quarterly or annual results29
- Nov 5, 2025Reported quarterly or annual results31
- Aug 6, 2025Reported quarterly or annual results32
- May 7, 2025Reported quarterly or annual results34
- Mar 5, 2025Reported quarterly or annual results35
- Nov 6, 2024Reported quarterly or annual results36
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
226 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 39 major events, 154 insider forms, 12 other. The latest 20:
- Oct 15, 20264 EDGAR
- Oct 15, 20264 EDGAR
- Oct 15, 20264 EDGAR
- Oct 15, 20264 EDGAR
- Oct 2, 20264 EDGAR
- Oct 2, 20264 EDGAR
- Sep 28, 20264 EDGAR
- Sep 23, 20268-K EDGAR
- Sep 22, 2026DEF 14A EDGAR
- Sep 11, 2026PRE 14A EDGAR
- Sep 1, 20264 EDGAR
- Aug 13, 202610-Q EDGAR
- Aug 12, 20268-K EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
- Jul 17, 20264 EDGAR
The 226 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
11 open-market trades by officers, directors and large owners since October 2021: 3 buys and 8 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 22, 2026 | Levine Jon RPresident and CEO | Buy | 60,000 | $0.08 | $4.6K | Form 4 |
| May 20, 2026 | Levine Jon RPresident and CEO | Buy | 40,000 | $0.08 | $3.2K | Form 4 |
| Dec 12, 2025 | Shaw TimothyChief Operating Officer | Buy | 45,455 | $0.11 | $5.0K | Form 4 |
| Apr 29, 2024 | Shaw TimothyChief Operating Officer | Sale | 40,205 | $0.26 | $10.5K | Form 4 |
| Apr 29, 2024 | Levine Jon RPresident and CEO | Sale | 50,031 | $0.26 | $13.0K | Form 4 |
| Mar 7, 2024 | Shaw TimothyChief Operating Officer | Sale | 15,348 | $0.23 | $3.5K | Form 4 |
| Mar 7, 2024 | Levine Jon RPresident and CEO | Sale | 16,529 | $0.23 | $3.8K | Form 4 |
| Oct 27, 2023 | Levine Jon RPresident and CEO | Sale | 41,590 | $0.32 | $13.3K | Form 4 |
| Oct 27, 2023 | Shaw TimothyChief Operating Officer | Sale | 33,272 | $0.32 | $10.6K | Form 4 |
| Apr 28, 2023 | Shaw TimothyChief Operating Officer | Sale | 39,371 | $0.37 | $14.6K | Form 4 |
| Apr 28, 2023 | Levine Jon RPresident and CEO | Sale | 49,393 | $0.38 | $18.8K | Form 4 |
From Forms 4 filed with the SEC.
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Canton Hathaway, LLC | 645,100 | $45.2K | 0.0% | No change |
| Game Plan Financial Advisors, LLC | 100 | $7 | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How MARIMED INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARMARIMED INC.1
- CIK0001522767
- Employer ID (EIN)27-46727454
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company4
- Incorporated inDelaware4
- Fiscal year endsDecember 311
- Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address10 Oceana Way, 2Nd Floor, Norwood, MA 020621
- Phone781-277-00071
- Shares outstanding403,040,674 as of Aug 10, 202612
- Public float$22.6M as of Jun 30, 20254
- AuditorM&K CPAS, PLLC, The Woodlands, TX PCAOB ID 2738; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceJun 9, 20111
- Filings376 in all: 4 (168), 8-K (72), 10-Q (46), 10-K (15), 3 (15), UPLOAD (9), DEF 14A (8), NT 10-K (7)1
All 24 form types
NT 10-Q (6), 10-12G/A (5), ARS (4), CORRESP (4), 10-Q/A (3), 10-K/A (2), PRE 14A (2), S-8 (2), 10-12G (1), 3/A (1), 424B3 (1), DEF 14C (1), EFFECT (1), PRE 14C (1), S-3 (1), SC 13G/A (1)
- Latest filingsAnnual report (10-K) Mar 12, 2026
Quarterly report (10-Q) Aug 13, 2026
Proxy statement (DEF 14A) Sep 22, 2026
Latest 8-K (8-K) Sep 23, 2026
Risk factors and legal proceedings
The risks MARIMED INC. names in Item 1A of its 10-K filed Mar 12, 2026: 36 risks under these headings, as written.4
- Risks Related to the Industry in Which We Operate
- Cannabis remains illegal under United States federal law.
- The cannabis industry is relatively new.
- We operate in a highly regulated sector and may not always succeed in complying fully with applicable regulatory requirements in all jurisdictions where we carry on business.
- As a cannabis business, we may lack access to United States bankruptcy protections.
- Cannabis businesses may be subject to civil asset forfeiture.
- Risks Related to Our Current Operations and Our Expansion Plan
- Our future growth is dependent on additional states legalizing cannabis.
- Our strategic growth plan is subject to regulatory hurdles.
- We face increasing competition that may materially and adversely affect our business, financial condition and results of operations.
- We are subject to limits on our ability to own the licenses necessary to operate our business, which could adversely affect our ability to grow our business and market share in certain states.
- We may not be able to obtain or maintain necessary permits and authorizations.
The other 26 risks
- We may have difficulty accessing the service of banks, which may make it difficult for us to operate in certain markets.
- We are subject to constraints on and differences in marketing our products under varying state laws.
- We face risks relating to our products.
- Our insurance coverage may be inadequate to cover all significant risk exposures.
- It may be difficult to evaluate us based on our past performance because the cannabis industry is volatile and still evolving.
- If our goodwill or intangible assets become impaired, we may be required to record a significant charge to earnings.
- Our quarterly revenue and operating results are unpredictable and may fluctuate significantly from quarter to quarter, which could adversely affect our business, results of operations and the trading price of our common stock.
- As a cannabis business, the IRS takes the view that we are subject to certain tax deduction limitations that may have a material adverse effect on our business, financial condition and results of operations.
- The IRS’s interpretations of Section 280E of the Code substantially limits our ability to deduct certain expenses from our federal taxable income for U.S. tax purposes.
- The Company may face enforcement actions by tax authorities if there are disagreements over the deductibility of operating expenses, particularly in areas subject to complex or evolving regulations. If we fail in our challenge of the validity of existing federal tax liens, or are unable to negotiate acceptable payment terms, our liquidity and business operations could be adversely affected.
- Our medical marijuana business may be impacted by consumer perception of the cannabis industry, which we cannot control or predict.
- We face inherent risks of product liability claims if anyone is harmed by the use of our products.
- Product recalls could result in a material and adverse impact on our business, financial condition, and results of operations.
- We are subject to risks related to growing an agricultural product.
- In the event we require additional financing and access to capital, the covenants and restrictions in our existing debt agreement may limit our options.
- Anti-Money Laundering Laws in the United States may limit access to funds from banks and other financial institutions.
- Failure to hire and retain key personnel, or the loss of any of our executive officers, could negatively impact our ability to meet our business objectives and impair our future growth.
- Cybersecurity Risks
- The occurrence of cybersecurity incidents, or a deficiency in our cybersecurity or in those of any of our third-party service providers, could negatively impact our business by causing a financial loss, significant disruption to our operations, a compromise or corruption of our confidential information or damage to our business relationships or reputation, all of which could negatively impact our business, financial condition and results of operations.
- Although we maintain insurance coverage for certain cybersecurity risks, there can be no guarantee that all costs, damages, expenses or losses incurred will be fully insured.
- Risks Related to Our Common Stock
- The market for our common stock may be limited for holders of our securities who live in the United States.
- Possible issuances of our capital stock would cause dilution to our existing stockholders.
- The exercise or conversion of outstanding warrants and options into common stock will dilute the percentage ownership of our other stockholders. Additionally, the sale of such common stock or other common stock in the open market could adversely affect the market price of our common stock.
- The market price of our common stock has been historically volatile and could continue to be volatile.
- We are an “emerging growth company” and will be able to take advantage of reduced disclosure requirements applicable to emerging growth companies, which could make our common stock less attractive to investors.
- If we fail to comply with the continued listing standards of the OTCQX tier of the OTC Markets Group, our common stock could be removed from the OTCQX marketplace. Any such removal could materially and adversely impact the market value and liquidity of our common stock.
- Our internal controls over financial reporting may not be effective, and our independent auditors may not be able to certify as to their effectiveness, which could have a significant and adverse effect on our business.
Legal proceedings
There has been no material change to the status of the Company’s previously reported legal proceedings.
From time to time, the Company may become involved in litigation or regulatory proceedings in the ordinary course of its business, including litigation or regulatory proceedings that could become more material to the Company's business. The cannabis industry is highly regulated, and many aspects of the Company's business involve substantial risk of liability. Further, in past years, there has been an increasing incidence of litigation involving the cannabis industry including class action suits that generally seek substantial damages, and in some cases, punitive damages. Compliance problems that are reported to federal/state regulatory authorities, by dissatisfied customers are often investigated by such regulatory bodies, and, if pursued by a regulatory body or customer, may rise to the level of litigation or disciplinary action.
Further, as a significant employer of full- and part-time employees, from time to time in the ordinary course of business, the Company faces claims and threatened claims from former employees alleging wrongful termination and other similar alleged wrongdoing, which the Company disputes and which are not material.
The opening of Item 3, Legal Proceedings.4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARMARIMED INC. filings on SEC EDGAR
- 2SEC EDGARMARIMED INC. filings on SEC EDGAR
- 3
- 4
- 5SEC EDGARMARIMED INC. 10-K for fiscal 2025
- 6SEC EDGARMARIMED INC. 10-K for fiscal 2019
- 7SEC EDGARMARIMED INC. 10-K for fiscal 2020
- 8SEC EDGARMARIMED INC. 10-K for fiscal 2021
- 9SEC EDGARMARIMED INC. 10-K for fiscal 2022
- 10SEC EDGARMARIMED INC. 10-K for fiscal 2023
- 11SEC EDGARMARIMED INC. 10-Q for fiscal 2026
- 12SEC EDGARMARIMED INC. 10-Q for fiscal 2026
- 13SEC EDGARMARIMED INC. 10-K for fiscal 2019
- 14
- 15SEC EDGARMario Pinho, Chief financial officer
- 16
- 17
- 18SEC EDGARKathleen Tucker, Board member
- 19SEC EDGARDavid R. Allen, Board member
- 20SEC EDGAREva M.d. Selhub, Board member
- 21SEC EDGARThomas Kidrin, Board member
- 22SEC EDGAREdward J. Gildea, Board member
- 23SEC EDGARJay Coleman, Board member
- 24SEC EDGARRobert N. Fireman, Board member
- 25SEC EDGAROther events
- 26SEC EDGARResults of operations
- 27SEC EDGARShareholder vote
- 28SEC EDGARResults of operations
- 29SEC EDGARResults of operations
- 30
- 31SEC EDGARResults of operations
- 32SEC EDGARResults of operations
- 33SEC EDGARShareholder vote
- 34SEC EDGARResults of operations
- 35SEC EDGARResults of operations
- 36SEC EDGARResults of operations